Literature DB >> 19168522

Rapid left ventricular recovery after cabergoline treatment in a patient with peripartum cardiomyopathy.

Jonas S S G de Jong1, Kirsten Rietveld, Laura T van Lochem, Berto J Bouma.   

Abstract

The aetiology of peripartum cardiomyopathy (PPCM) is still largely unknown. Recent evidence suggests that the breakdown products from prolactin can induce cardiomyopathy. Prolactin secretion can be reduced with bromocriptine which had beneficial effects in a small study. We present a case of a patient with PPCM who received cabergoline, a strong and long lasting antagonist of prolactin secretion. Following treatment, her prolactin levels dropped swiftly. N-terminal pro-BNP levels, which had remained high up to that point, dropped within 1 day (7006 to 4408 pg/mL). Echocardiographic left ventricular ejection fraction recovered from 26% on day 4 postpartum to 32% and later 47% on days 2 and 5 after cabergoline treatment. To our knowledge, this is the first description of a case of PPCM in which cabergoline was administered.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19168522      PMCID: PMC2639410          DOI: 10.1093/eurjhf/hfn034

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  12 in total

1.  Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy.

Authors:  U Elkayam; P P Tummala; K Rao; M W Akhter; I S Karaalp; O R Wani; A Hameed; I Gviazda; A Shotan
Journal:  N Engl J Med       Date:  2001-05-24       Impact factor: 91.245

2.  Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review.

Authors:  G D Pearson; J C Veille; S Rahimtoola; J Hsia; C M Oakley; J D Hosenpud; A Ansari; K L Baughman
Journal:  JAMA       Date:  2000-03-01       Impact factor: 56.272

3.  Frequency of Brugada-type ECG pattern (Brugada sign) in Southern Turkey.

Authors:  Abdi Bozkurt; Dilek Yas; Gülsah Seydaoglu; Esmeray Acartürk
Journal:  Int Heart J       Date:  2006-07       Impact factor: 1.862

4.  Incidence, mortality, and racial differences in peripartum cardiomyopathy.

Authors:  Somjot S Brar; Steven S Khan; Gagandeep K Sandhu; Michael B Jorgensen; Neil Parikh; Jin-Wen Y Hsu; Albert Yuh-Jer Shen
Journal:  Am J Cardiol       Date:  2007-06-06       Impact factor: 2.778

5.  Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy.

Authors:  Olaf Forster; Denise Hilfiker-Kleiner; Aftab A Ansari; J Bruce Sundstrom; Elena Libhaber; Winnie Tshani; Anthony Becker; Anthony Yip; Gunnar Klein; Karen Sliwa
Journal:  Eur J Heart Fail       Date:  2008-09-02       Impact factor: 15.534

6.  The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy.

Authors:  Karen Sliwa; Daniel Skudicky; Geoffrey Candy; Anette Bergemann; Mark Hopley; Pinhas Sareli
Journal:  Eur J Heart Fail       Date:  2002-06       Impact factor: 15.534

7.  Myocarditis and long-term survival in peripartum cardiomyopathy.

Authors:  G M Felker; C J Jaeger; E Klodas; D R Thiemann; J M Hare; R H Hruban; E K Kasper; K L Baughman
Journal:  Am Heart J       Date:  2000-11       Impact factor: 4.749

Review 8.  Peripartum cardiomyopathy.

Authors:  Karen Sliwa; James Fett; Uri Elkayam
Journal:  Lancet       Date:  2006-08-19       Impact factor: 79.321

9.  Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy.

Authors:  G M Felker; R E Thompson; J M Hare; R H Hruban; D E Clemetson; D L Howard; K L Baughman; E K Kasper
Journal:  N Engl J Med       Date:  2000-04-13       Impact factor: 91.245

10.  A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy.

Authors:  Denise Hilfiker-Kleiner; Karol Kaminski; Edith Podewski; Tomasz Bonda; Arnd Schaefer; Karen Sliwa; Olaf Forster; Anja Quint; Ulf Landmesser; Carola Doerries; Maren Luchtefeld; Valeria Poli; Michael D Schneider; Jean-Luc Balligand; Fanny Desjardins; Aftab Ansari; Ingrid Struman; Ngoc Q N Nguyen; Nils H Zschemisch; Gunnar Klein; Gerd Heusch; Rainer Schulz; Andres Hilfiker; Helmut Drexler
Journal:  Cell       Date:  2007-02-09       Impact factor: 41.582

View more
  6 in total

Review 1.  Bromocriptine for the Treatment of Peripartum Cardiomyopathy.

Authors:  Tobias Koenig; Johann Bauersachs; Denise Hilfiker-Kleiner
Journal:  Card Fail Rev       Date:  2018-05

Review 2.  Case report and mini literature review: anesthetic management for severe peripartum cardiomyopathy complicated with preeclampsia using sufetanil in combined spinal epidural anesthesia.

Authors:  Pradipta Bhakta; Pragnyadipta Mishra; Anamika Bakshi; Vijay Langer
Journal:  Yonsei Med J       Date:  2011-01       Impact factor: 2.759

3.  Cabergoline as an adjuvant to standard heart failure treatment in peripartum cardiomyopathy: A case report and review of the literature.

Authors:  Giuseppe Caruso; Annalisa Scopelliti; Sara Scaramuzzino; Giuseppina Perrone; Paola Galoppi; Innocenza Palaia; Ludovico Muzii; Pierluigi Benedetti Panici; Roberto Brunelli
Journal:  Case Rep Womens Health       Date:  2020-12-07

Review 4.  Fontan Circulation Might be Associated with Peripartum Cardiomyopathy: A Review of Mechanistic and Clinical Aspects.

Authors:  Kenan Yalta; Ertan Yetkin; Gokay Taylan
Journal:  Curr Cardiol Rev       Date:  2021

5.  Peripartum cardiomyopathy presenting with predominant left ventricular diastolic dysfunction: efficacy of bromocriptine.

Authors:  Piercarlo Ballo; Irene Betti; Giuseppe Mangialavori; Leandro Chiodi; Gherardo Rapisardi; Alfredo Zuppiroli
Journal:  Case Rep Med       Date:  2012-11-22

Review 6.  Peripartum cardiomyopathy: current state of knowledge, new developments and future directions.

Authors:  Murat Biteker; Kadir Kayatas; Dursun Duman; Muhsin Turkmen; Biykem Bozkurt
Journal:  Curr Cardiol Rev       Date:  2014-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.